Table 2 Summary of results of Kaplan-Meier survival analyses
Full cohort | Full cohort | Malignant | Noninvasive | ||||
|---|---|---|---|---|---|---|---|
Total | IPMN | MCN | IPMN | MCN | IPMN | MCN | |
Overall survival | |||||||
At risk, (n) | 245 | 218 | 27 | 93 | 8 | 125 | 19 |
Median time, months (IQR) | 34 (19–61) | 38.5 (20–63) | 24 (16–25) | 35 (19–63) | 20 (13–23.5) | 42 (20–64) | 20 (16–26) |
Deaths, % (n) | 2.9% (7) | 2.8% (6) | 3.7% (1) | 6.5% (6) | 12.5% (1) | 0% (0) | 0% (0) |
1-year, % | 98% | 98.75% | 95.7% | 97.1% | 87.5% | 100% | 100% |
3-year, % | 95.9% | 98.75% | 95.7% | 94.2% | 87.5% | 100% | 100% |
5-year, % | 93% | 97.5% | 95.7% | 91.3% | 87.5% | 100% | 100% |
Log-rank, (p) | p = 0.48 | p = 0.33 | p = 1.0 | ||||
Disease-free survival | |||||||
At risk, (n) | 245 | 218 | 27 | 93 | 8 | 125 | 19 |
Median time, months (IQR) | 24 (16–53) | 26 (17–54) | 20 (14–25) | 23 (14–52) | 18 (8–24) | 30 (19–58) | 20 (16–26) |
Recurrence, % (n) | 15.1% (37) | 15.6% (34) | 11.1% (3) | 23.7% (22) | 37.5% (3) | 9.6% (12) | 0% (0) |
1-year, % | 86.4% | 85.7% | 91.3% | 75.3% | 75.0% | 94% | 100% |
3-year, % | 81.8% | 81.1% | 87.0% | 74.0% | 62.5% | 90% | 100% |
5-year, % | 81.3% | 80.6% | 87.0% | 71.4% | 62.5% | 88% | 100% |
Log-rank, (p) | p = 0.67 | p = 0.27 | p = 0.2 | ||||